Perimeter Medical Imaging AI (PINK) AI Stock Analysis

• Market Cap: C$23.85M
• Dividend Yield: N/A
• Average Volume (3M): 223.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 113.85%
• EPS Growth: 11.38%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 93,513,840
• 10 Day Avg. Volume: 113,900
• 30 Day Avg. Volume: 223,787
• PEG Ratio: 0.24
• Price to Book (P/B): 2.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.29
• Enterprise Value/Market Cap: 1.90
• Enterprise Value/Revenue: 19.10
• Enterprise Value/Gross Profit: 84.51
• Enterprise Value/Ebitda: -0.87
• 1Y Price Target: C$3.00
• Price Target Upside: 1053.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: ―

Perimeter Medical Imaging AI is positioned in a growth phase with strong revenue increases and promising clinical advancements towards FDA approval. However, persistent net losses, cash flow constraints, and bearish technical indicators pose significant challenges. The valuation remains unattractive, but recent strategic corporate events offer potential for future expansion.

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company Description

Perimeter Medical Imaging AI (PINK) is a medical technology company focused on enhancing the accuracy of cancer surgeries through advanced imaging solutions. The company operates primarily in the healthcare and medical technology sectors, offering innovative imaging tools that assist surgeons in identifying cancerous tissues during operations. Their flagship product is an AI-powered imaging platform designed to provide real-time, high-resolution images, aiding in the precise removal of cancerous tissues and potentially reducing the need for repeat surgeries.

How the Company Makes Money

Perimeter Medical Imaging AI makes money primarily through the sale and leasing of its imaging devices to hospitals and surgical centers. The company also generates revenue from service agreements, maintenance contracts, and by offering training and support for its technology. Additionally, Perimeter may engage in partnerships with healthcare providers and research institutions to expand the application of its technology and drive adoption, which can further contribute to revenue through collaborative agreements and research grants. Key revenue streams include direct sales of imaging devices, recurring revenue from ongoing service and maintenance, and strategic partnerships that enhance their market presence.

Perimeter Medical Imaging AI Financial Statement Overview

Summary

Perimeter Medical Imaging AI is showing strong revenue growth and a healthy gross margin of 63.2%. However, the company is still operating at a net loss, has negative return on equity, and faces cash flow challenges, relying heavily on external financing.

Income Statement

The company has shown a strong revenue growth rate, increasing from CAD 403,533 in 2023 to CAD 846,194 in 2024, indicating positive momentum. However, it is still operating at a net loss, with a negative net profit margin of -1581% for 2024. The gross profit margin is relatively high at 63.2%, highlighting some operational efficiency. Nonetheless, persistent losses in EBIT and EBITDA suggest ongoing operational challenges.

Balance Sheet

The balance sheet is relatively stable, with a low debt-to-equity ratio of 0.01, indicating conservative leverage. The equity ratio stands at 73%, showing a strong equity base relative to total assets. However, the company has been consistently reporting net losses, impacting the overall return on equity, which remains negative.

Cash Flow

The cash flow analysis indicates challenges with a negative free cash flow growth rate and substantial negative operating cash flow. The operating cash flow to net income ratio is slightly above 1, suggesting cash flow issues relative to income. However, the company has managed to raise capital through financing activities, which may support short-term liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	846.19K	403.53K	132.77K	11.34K	0.00
Gross Profit	535.11K	206.42K	100.63K	5.04K	-47.57K
EBITDA	-12.64M	-17.92M	-11.72M	-15.95M	-6.11M
Net Income	-13.39M	-18.94M	-3.59M	-16.76M	-8.00M
Balance Sheet
Total Assets	14.33M	27.09M	34.60M	9.98M	13.16M
Cash, Cash Equivalents and Short-Term Investments	6.18M	18.43M	28.44M	5.14M	11.70M
Total Debt	137.48K	192.89K	325.68K	441.17K	400.81K
Total Liabilities	3.87M	7.10M	8.49M	2.56M	2.40M
Stockholders Equity	10.45M	15.06M	26.11M	7.42M	10.76M
Cash Flow
Free Cash Flow	-16.90M	-15.17M	-13.86M	-16.03M	-8.26M
Operating Cash Flow	-14.72M	-14.70M	-11.87M	-13.91M	-8.26M
Investing Cash Flow	-1.90M	206.01K	-1.75M	-1.45M	7.24M
Financing Cash Flow	8.58M	234.47K	40.28M	10.06M	9.84M

Perimeter Medical Imaging AI Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Neutral. The current price of 0.26 is above the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.32, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.40 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	61 Neutral	C$106.44M	―	-8.34%	―	0.69%	-95.27%
ASG	55 Neutral	C$24.20M	―	-23.87%	―	18.97%	17.57%
PRN	54 Neutral	C$247.34M	―	-66.14%	―	51.21%	15.33%
TLT	51 Neutral	C$48.91M	―	-291.48%	―	-8.63%	7.04%
PINK	50 Neutral	C$23.85M	―	-163.62%	―	113.85%	11.38%
Sector *	46 Neutral	C$194.85M	-4.28	-8.56%	2.84%	13.52%	-1.74%
VPT	44 Neutral	C$21.68M	―	207.08%	―	280.56%	-7.28%

Perimeter Medical Imaging AI Corporate Events

HonorHealth Adopts Perimeter’s Advanced Imaging Technology in Arizona

Perimeter Medical Imaging AI announced that HonorHealth is the first healthcare system in Arizona to implement its S-Series OCT technology, enhancing surgical decision-making with real-time, high-resolution imaging of tissue margins. This deployment marks a significant step in Perimeter’s nationwide expansion, increasing access to their technology in a major metropolitan area and reflecting the growing demand for improved surgical outcomes.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.

To see Spark’s full report on TSE:PINK stock, click here.

Perimeter Medical Imaging AI to Present at 2025 Healthcare Investor Conference

Perimeter Medical Imaging AI announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where it will present updates on its business. This participation underscores Perimeter’s ongoing efforts to enhance its industry presence and communicate its technological advancements, potentially impacting its market positioning and stakeholder engagement.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.

To see Spark’s full report on TSE:PINK stock, click here.

Perimeter Medical Imaging AI Announces Public Offering to Boost Commercialization Efforts

Perimeter Medical Imaging AI, Inc. announced a proposed public offering of units, consisting of common shares and purchase warrants, to raise funds for the commercialization of its technology, clinical evidence establishment, and product development. The offering, expected to close by the end of April 2025, will be conducted on a ‘best efforts’ basis with A.G.P. Canada Investments ULC as the agent, and aims to strengthen the company’s market position and operational capabilities.

Perimeter Medical Imaging AI Reports Strong 2024 Growth and Advances B-Series OCT Development

Perimeter Medical Imaging AI reported significant financial growth in 2024, with a 303% increase in Q4 revenues compared to the previous year, driven by the adoption of its S-Series OCT systems. The company is advancing its B-Series OCT system, having successfully completed a pivotal trial for breast-conserving surgeries and submitted a PMA application to the FDA. This progress positions Perimeter for further expansion and potential regulatory approval, which could enhance its market position and impact stakeholders positively.

Perimeter Medical Imaging AI to Announce 2024 Financial Results

Perimeter Medical Imaging AI announced it will release its fourth quarter and full year 2024 financial results on March 26, 2025, followed by a conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it may impact the company’s operations and industry positioning, especially considering its ongoing clinical trials and the potential market introduction of its next-generation imaging technology.

Perimeter Medical Imaging AI Submits FDA Application for Advanced Imaging System

Perimeter Medical Imaging AI has submitted a Premarket Approval application to the FDA for its B-Series OCT system with ImgAssist AI 2.0, aimed at improving outcomes in breast-conserving surgeries. The pivotal trial showed significant results in reducing residual cancer during surgery, suggesting potential widespread adoption among breast cancer surgeons if approved, marking a significant milestone for the company’s operations and industry positioning.

Perimeter Medical’s Pivotal Trial Results to be Presented at ASBrS 2025

Perimeter Medical Imaging AI announced that its pivotal trial results for the B-Series OCT with ImgAssist AI 2.0 will be presented at the 2025 Annual Meeting of the American Society of Breast Surgeons. The trial showed a statistically significant reduction in residual cancer during surgery, supporting the company’s efforts to gain FDA approval for their next-generation imaging system. This development could enhance the adoption of their technology, providing surgeons with improved tools for breast cancer surgery.

Perimeter Medical Imaging AI to Trade on OTCQX, Eyes U.S. Expansion

Perimeter Medical Imaging AI announced that its common shares will begin trading on the OTCQX Best Market, enhancing its visibility and efforts to expand its U.S. shareholder base. This move follows positive results from a pivotal study supporting the company’s FDA premarket approval submission for its B-Series OCT with ImgAssist AI, which demonstrated significant improvements in surgical outcomes, potentially reducing the need for reoperations.